Literature DB >> 18440705

Prognostic factors for renal cell carcinoma.

D Furniss1, P Harnden, N Ali, P Royston, T Eisen, R T Oliver, B W Hancock.   

Abstract

Renal cell carcinoma is a relatively uncommon tumour with a widely varying prognosis depending on several tumour and clinical factors. This review discusses these factors and critically appraises their value both as individual markers and when they are incorporated into scoring systems/models or algorithms. Disease stage (assessed pathologically and/or clinically) and performance status have the strongest evidence as helpful individual prognostic markers but a better discrimination is obtained by combining these and adding in various other indices. Prospective validation of such integrated prognostic models will be essential.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18440705     DOI： 10.1016/j.ctrv.2007.12.008

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  8 in total

1.  Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients.

Authors:  Ana L Teixeira; Marta Ferreira; Joana Silva; Mónica Gomes; Francisca Dias; Juliana I Santos; Joaquina Maurício; Francisco Lobo; Rui Medeiros
Journal:  Tumour Biol       Date:  2013-12-31

2.  The prognostic value of cyclin D1 in renal cell carcinoma.

Authors:  M S Lima; R A Pereira; R S Costa; S Tucci; M Dantas; V F Muglia; R C Ravinal; G E Barros-Silva
Journal:  Int Urol Nephrol       Date:  2013-11-17       Impact factor: 2.370

3.  Renal cell carcinoma with unusual metastasis to the small intestine manifesting as extensive polyposis: successful management with intraoperative therapeutic endoscopy.

Authors:  Pankaj G Vashi; Elham Abboud; Digant Gupta
Journal:  Case Rep Gastroenterol       Date:  2011-08-22

4.  A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.

Authors:  Hideyuki Akaza; Mototsugu Oya; Masafumi Iijima; Ichinosuke Hyodo; Akihiko Gemma; Hiroshi Itoh; Masatoshi Adachi; Yutaka Okayama; Toshiyuki Sunaya; Lyo Inuyama
Journal:  Jpn J Clin Oncol       Date:  2015-07-22       Impact factor: 3.019

5.  Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics.

Authors:  Rosa Ragone; Fabio Sallustio; Sara Piccinonna; Monica Rutigliano; Galleggiante Vanessa; Silvano Palazzo; Giuseppe Lucarelli; Pasquale Ditonno; Michele Battaglia; Francesco Paolo Fanizzi; Francesco Paolo Schena
Journal:  Diseases       Date:  2016-01-22

6.  Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now?

Authors:  Ana L Teixeira; Francisca Dias; Mónica Gomes; Mara Fernandes; Rui Medeiros
Journal:  J Kidney Cancer VHL       Date:  2014-12-24

7.  Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis.

Authors:  Zhicong Chen; Yonghao Zhan; Jieshan Chi; Shuyuan Guo; Xinliang Zhong; Anbang He; Jianrong Zheng; Yanqing Gong; Xuesong Li; Liqun Zhou
Journal:  EBioMedicine       Date:  2018-07-21       Impact factor: 8.143

8.  Methylenetetrahydrofolate Dehydrogenase 1 (MTHFD1) is Underexpressed in Clear Cell Renal Cell Carcinoma Tissue and Transfection and Overexpression in Caki-1 Cells Inhibits Cell Proliferation and Increases Apoptosis.

Authors:  Donglin He; Zhihai Yu; Sheng Liu; Hong Dai; Qing Xu; Feng Li
Journal:  Med Sci Monit       Date:  2018-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.